Quest Diagnostics Incorporated (NYSE: DGX) — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Although the request references 2022 Q4, this filing reports annual results; it does not provide a clear standalone fourth-quarter financial summary in the supplied text. Amounts below are in U.S. dollars.
Business context
Quest is a large U.S. provider of clinical laboratory and anatomic pathology testing, diagnostic information services, and related solutions. Diagnostic Information Services (DIS) generated 97% of 2022 revenue; Diagnostic Solutions (DS), including risk assessment and healthcare IT, generated the balance. The company processed approximately 208 million test requisitions during 2022. COVID-19 testing represented 15% of revenue, down from 26% in 2021.
Key financial results
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Net revenue | $9.883 billion | $10.788 billion | Down 8.4% |
| Operating income | $1.428 billion | $2.381 billion | Down 40.0% |
| Operating margin | 14.5% | 22.1% | Down 7.6 percentage points |
| Net income attributable to Quest | $946 million | $1.995 billion | Down 52.6% |
| Diluted EPS | $7.97 | $15.55 | Down 48.7% |
| Cash from operating activities | $1.718 billion | $2.233 billion | Down $515 million |
| Capital expenditures | $404 million | $403 million | Up $1 million |
- Revenue mix and volume: COVID-19 testing revenue fell to $1.454 billion from $2.770 billion. Base-business revenue, including acquisitions, rose 5.6% to $8.429 billion. DIS requisitions declined 4.5% overall, while base-business volume rose 2.2%; revenue per requisition declined 4.5% overall but rose 3.0% in the base business.
- Cash and liquidity: Cash and cash equivalents were $315 million at year-end, versus $872 million a year earlier. The company reported approximately $1.2 billion of available capacity under credit facilities, with no borrowings outstanding on those facilities. Management said cash, operating cash flow, and borrowing capacity should fund working capital, investment, debt service, dividends, repurchases, and growth opportunities for the foreseeable future.
- Debt: Long-term debt, net of current portion, was $3.978 billion at year-end. The company reported compliance with applicable credit-facility covenants. Scheduled debt maturities include $302 million in 2024, $601 million in 2025, and $502 million in 2026.
- Shareholder returns: Quest repurchased 10.1 million shares for $1.4 billion in 2022 and paid $305 million in dividends. In February 2023, it announced a 7.6% quarterly dividend increase to $0.71 per share and authorized an additional $1 billion of repurchases.
Material changes and unusual items
- Lower COVID-19 testing was the main driver of the revenue and earnings decline. Cost of services decreased 2.0%, but SG&A increased 8.5%, including higher wages, growth investments, and Quest for Health Equity support.
- 2022 diluted EPS included net identified items that reduced EPS by $1.98, including amortization, $93 million of Quest for Health Equity charges, $88 million of restructuring and integration charges, and losses on strategic investments. These items were partly offset by tax benefits. Management also noted EPS benefited from share repurchases.
- 2021 results included a $314 million pretax gain on the sale of Quest’s 40% interest in Q2 Solutions. This contributed to the steep year-over-year decline in reported 2022 operating and net income comparisons.
- Operating cash flow declined, primarily due to lower operating income, partly offset by $426 million less in income tax payments. Cash used in financing was $1.732 billion, including share repurchases and dividends.
- 2022 acquisitions included Pack Health and Summa Health’s outreach testing business; Quest also agreed to acquire select Northern Light Health outreach assets. A subsequent agreement to acquire select New York-Presbyterian laboratory assets was expected to close in the second quarter of 2023, subject to customary conditions.
Outlook, management commentary, and risks
- No full-year 2023 revenue or earnings guidance is provided in the supplied filing text. Management estimated approximately $400 million of 2023 capital expenditures.
- Management targets annual cost savings and productivity improvements of approximately 3% of costs through its Invigorate program; it said it approached that goal in 2022. The company’s stated growth aims include more than 2% annual revenue growth from strategic acquisitions and at least 8% annual growth in Advanced Diagnostics.
- Management sees opportunities from healthcare consolidation, demand for value and price transparency, consumer-initiated testing, and advanced diagnostics. It also cited reimbursement pressure, labor and inflation costs, and greater patient financial responsibility as challenges. PAMA reporting and related reimbursement changes were delayed until January 1, 2024; statutory Medicare laboratory reimbursement reductions for 2024–2026 are capped at 15% annually.
- Key risks include payer pricing and coverage changes, test-volume sensitivity to healthcare utilization, competition and in-house testing by health systems, FDA/LDT regulation, billing and reimbursement compliance, cybersecurity and privacy, workforce availability, inflation, and acquisition integration.
- Legal matters include pending class actions related to the AMCA and ReproSource data incidents, an ERISA plan lawsuit, and other proceedings and inquiries. The company said material legal losses were not probable at year-end; recorded legal reserves were $2 million. Professional liability reserves were $169 million, and management believes reserves and insurance cover currently estimated exposures.
- Quest reported $384 million of noncancelable future purchase commitments. It also disclosed contingent lease obligations that could total several hundred million dollars under certain predecessor leases, but considers the likelihood of payment remote and recorded no liability for them.
- PwC gave unqualified opinions on the financial statements and internal control over financial reporting; management also concluded controls were effective at December 31, 2022.
Most important facts for investors to verify
- Whether base-business revenue and requisition growth can offset continued normalization of COVID-19 testing and any price or payer-mix pressure.
- How much of the earnings decline reflects nonrecurring 2021 Q2 Solutions gains and 2022 identified charges, versus ongoing margin changes.
- Whether the company achieves its cost-savings and Advanced Diagnostics growth targets while absorbing wage, supply, and inflation costs.
- Potential effects of PAMA reimbursement changes, payer denials, patient concessions, and shifts toward capitated or value-based arrangements.
- Debt maturities, capital allocation, and the sustainability of dividends and repurchases alongside acquisitions and planned capital spending.
- Developments in disclosed data-security litigation and other legal or regulatory matters, and the adequacy of receivables, professional-liability, and legal reserves.